Corona හැදෙන්නේ නැති එන්නතක් හොයාගෙන

Nadun26

Well-known member
  • Apr 27, 2015
    14,157
    12,707
    113
    38
    screenshot-nethnews.lk-2021.08.21-11_17_26.png


    Source http://nethnews.lk/article/88651

    https://www.bloomberg.com/news/arti...st-dna-based-covid-shot-boosting-vaccine-plan
    https://www.reuters.com/business/he...as-covid-19-vaccine-emergency-use-2021-08-20/
     

    Bounty_Hunter

    Well-known member
  • Apr 18, 2015
    3,399
    5,755
    113
    අනේ බන්
    නිවුස් එ‍ෙකේම තියෙනවා 66%යි වැඩ කලේ කියලා
    අනික් 34% කොවිඩ් හැදිලා කුකුලෝ

    උඹයි උඹේ ගණනුයි නම්
    66% hadune nethi eka special added benefit ekak ban. eka neme vaccine eke balaporoththuwa. dan tiyena vaccines ekka baluwama 66% prevention kiyanneme loku win ekak. dan tiyena kisi vaccine ekak guaranty ekk denne ne prevention eka gana.

    habei news eke ne kochchara efficacy ekak tiyenawada kiyala.
    samahara wita 100% at severity of illness and hospitalization walin, eth ekka 66% prevention kiyanne supiri.
    dan tiyena hama vaccine ekak ma over 60% against severity of illness and hospitalization + 0% promise to prevent infection
     

    imhotep

    Well-known member
  • Mar 29, 2017
    14,866
    8
    35,456
    113
    There are many DNA vaccines under development and also on trial across the globe from the US to Australia. These can be quite effective depending on the design method. In the current settings with the variants it's the way ahead.
    The only other hope is an anti-viral drug which will negate the mass scale vaccinations. (y)
     

    Sri_Sampath

    Well-known member
  • Jan 26, 2010
    14,741
    12,766
    113
    හැදෙන්නේ නෑ කියන්නේ කොහොමද :baffled:

    Findings​

    Out of 126 individuals screened for eligibility. Forty-eight subjects (mean age 34·9 years) were enrolled and vaccinated in the Phase 1 study Overall, 12/48 (25%) subjects reported at least one AE (i.e. combined solicited and unsolicited) during the study. There were no deaths or serious adverse events reported in Phase 1 of the study. The proportion of subjects who seroconverted based on IgG titers on day 84 was 4/11 (36·36%), 4/12 (33·33%), 10/10 (100·00%) and 8/10 (80·00%) in the treatment Arm 1 (1 mg: Needle), Arm 2 (1 mg: NFIS), Arm 3 (2 mg: Needle) and Arm 4 (2 mg: NFIS), respectively.